Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 13/20 | 0.67 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15412881 | 0.94 | GPR119 (0.61) | GPR119HPGDKDM4EPKMRECQL | |
| SCHEMBL4097772 | 0.94 | GPR119 (0.60) | GPR119HPGDKDM4EPKMRECQL | |
| SCHEMBL26635122 | 0.91 | GPR119 (0.58) | GPR119HPGDKDM4EPKMRECQL | |
| SCHEMBL2676533 | 0.91 | GPR119 (0.58) | GPR119HPGDKDM4EPKMRECQL | |
| SCHEMBL2149117 | 0.91 | GPR119 (0.58) | GPR119HPGDKDM4EPKMRECQL | |
| SCHEMBL20303147 | 0.91 | GPR119 (0.58) | GPR119HPGDKDM4EPKMRECQL | |
| Ethylene SCHEMBL8479448 | 0.90 | GPR119 (0.57) | GPR119HPGDKDM4EPKMRECQL | |
| SCHEMBL7367546 | 0.90 | GPR119 (0.57) | GPR119HPGDKDM4EPKMRECQL | |
| SCHEMBL8479449 | 0.89 | GPR119 (0.57) | GPR119HPGDKDM4EPKMRECQL | |
| SCHEMBL7359200 | 0.89 | GPR119 (0.59) | GPR119HPGDKDM4EPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2615089-B1 | Pyrazoloquinoline compounds | ASTELLAS PHARMA INC (JP) | 2016-04-27 | — | — | EP | disclosed |
| EP-2615089-B1 | Pyrazoloquinoline compounds | ASTELLAS PHARMA INC (JP) | 2016-04-27 | — | — | EP | disclosed |
| US-8822448-B2 | Pyrazoloquinoline compound | ASTELLAS PHARMA INC. (JP) | 2014-09-02 | — | — | US | disclosed |
| US-8822448-B2 | Pyrazoloquinoline compound | ASTELLAS PHARMA INC. (JP) | 2014-09-02 | — | — | US | disclosed |
| US-20130225553-A1 | PYRAZOLOQUINOLINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2013-08-29 | — | — | US | disclosed |
| US-20130225553-A1 | PYRAZOLOQUINOLINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2013-08-29 | — | — | US | disclosed |
| EP-2615089-A1 | PYRAZOLOQUINOLINE COMPOUND | Astellas Pharma Inc. (JP) | 2013-07-17 | — | — | EP | disclosed |
| WO-2012033144-A1 | PYRAZOLOQUINOLINE COMPOUND | アステラス製薬株式会社 (JP) | 2012-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225553-A1 | PYRAZOLOQUINOLINE COMPOUND | PDE9A, PDE5A, PDE2A | GPR119 513/4885HPGD 329/4885KDM4E 1337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.